

Auditor's Report
On the extent of compliance with corporate governance rules

**To Messrs. / Ibn Sina Pharma Company
(Egyptian Joint Stock Company)**

To the Financial Regulatory Authority

Introduction

We tested the governance compliance report prepared by the management of Ibn Sina Pharma (Egyptian Joint Stock Company) for the fiscal year ended 31 December 2024.

Management Responsibility

The company's management is responsible for preparing and presenting a report on compliance with the rules of governance in accordance with the instructions issued by the Financial Supervisory Authority and the Egyptian Guide for Corporate Governance issued by the Egyptian Center of Directors and the relevant laws and decisions, and the responsibility of the management extends to identifying points of non-compliance and justifications.

Auditor's Responsibility

officials are limited to testing the information contained in the report on compliance with the rules of governance and to make a conclusion in light of the tests that have been performed, and we have tested the report of compliance with the rules of governance in accordance with the Egyptian standard for verification tasks No. (3000) "Verification tasks other than reviewing or examining historical financial information", and this standard requires compliance with the requirements of professional conduct, including the requirements of independence, and the planning and performance of the verification process to obtain confirmation that the report on compliance with the rules of governance is free of any significant and influential distortions, and includes testing the report of compliance with the rules of governance Obtaining mainly evidence from the observation and inquiries from the persons responsible for preparing the report on compliance with the rules of governance and access to documents when this is Appropriate.


We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for conclusion.

This report has been prepared to be submitted to the Financial Regulatory Authority at the request of the company's management, and not for any other purpose and therefore is suitable for use only for the purpose for which it was prepared.

Conclusion

The above-mentioned Corporate Governance Compliance Report reflects fairly and clearly in all its important aspects the Company's compliance with the Corporate Governance Rules during the financial year ended 31 December 2024 based on the instructions issued by the Financial Supervisory Authority and the Egyptian Corporate Governance Guide issued by the Egyptian Center of Directors and the relevant laws and decisions.

Cairo: 10 February 2025



Auditor
Essia Mohsen Alsayed Rifai
Register of Accountants and Auditors No. (6166)
Financial Regulatory Authority Register No. (192)
(Khaled El Ghannam & ESSIA REFAI Co.)

Corporate Governance Report FY 2024

Our management approach is built on fostering an environment of respect, trust, transparency, and accountability. In this regard, we built independent, effective structures to ensure the resilience of this spirit. Setting the mechanisms and tools that provide effective governance and creating the facilities necessary to govern ISP's operations and performance were essential to building the company's credibility. Through different approaches, we managed to keep the governance structures, laws, mechanisms, and processes simple to minimise non-compliance and increase clear communication between our Board of Directors and the Executives. The governance framework that Ibnsina adopted ensures a proper communication mechanism is set in place to guarantee transparency across its departments, affairs, and day-to-day operations. A system that establishes good governance practices is highly valued and protected by the Board of Directors and is crucial when evaluating Ibnsina's performance.

The committees play an integral role in ensuring operational compliance. Active committees are composed of members with a high level of expertise that qualifies them to provide direction, keep track of the business performance, implement legal obligations and maintain the company's performance in alignment with its primary mission. Such an approach is applied to maintain proper business control, manage business risks, define roles and responsibilities, manage and channel the flow of information most effectively and transparently, and uphold the discipline to allow Ibnsina Pharma to grow ethically and professionally.

Basic Data

| | |
|------------------------|--|
| Company purpose | <p>In accordance with the decision of the Extraordinary General Assembly held on 25/11/2021, Article 3 of the Company's Articles of Association was amended to become the purpose of the company as follows:</p> <p>Buying, selling wholesale, distribution, manufacturing, manufacturing with</p> |
|------------------------|--|

| | |
|--|---|
| | <p>others, packaging, transporting, storing, importing, exporting, owning and carrying out commercial and scientific advertising, marketing offers, public supplies, electronic commerce and commercial agencies for all pharmaceutical, human, biological, veterinary and pharmaceutical products Chemicals, cosmetics, food, nutritional supplements, pesticides, disinfectants of all kinds, medical and compensatory devices, laboratory and hospital supplies, equipment, tools and materials for laboratory reagents, packaging and advertising materials, whether locally manufactured or imported, in addition to the skills of the aforementioned products seals, as well as training, information supply, systems programs, consulting related to the aforementioned areas, rental and sale of administrative and storage spaces.</p> <p>It may have a business or participate in any way with companies that engage in business similar to its business or that may help it achieve its purpose in Egypt or abroad, and it may also merge into these companies or buy them or attach them to them, in accordance with the provisions of the law and its executive regulations.</p> |
|--|---|

| | | | |
|---|--------------------------|--|--|
| Duration of the company | 25 years | Date of listing on the ASE | 8/11/2017 |
| The law to which the company is subject | 159 of 1981 | Nominal value per share | Twenty-five piasters per share |
| Last Authorized Capital | 1 billion Egyptian pound | Last issued capital | EGP 252 Mill |
| Last paid-in capital | EGP 252 M | Number and date of registration in the commercial register | The company was registered in the commercial register under No. 6384 dated 8/1/2001 Cairo Investment Commercial Registry Office and the registration was erased from the commercial register to change the company's headquarters from Cairo Governorate to Qalyubia Governorate The company was registered in the commercial register under No. 10724 dated 6/1/2004 Cairo Investment Commercial Registry Office. |

Investor Relations:

| | |
|---------------------|---|
| contact person | Mohamed Mahmoud Shawky |
| Head Office Address | industrial Zone – Plots 2/3 Block 12/15 Northern Extension of Obour City Qalyubia |
| Telephone: 44891102 | Fax numbers: 44891103 |
| Website | www.ibnsina-pharma.com |
| Email | ir@ibnsina-pharma.com |

Shareholders Structure

| Shareholders owning 5% of more | Number of Shares | % |
|---|--------------------|---------------|
| Faisal Islamic Bank of Egypt | 140,981,127 | 13.99% |
| THE EUROPEAN BANK FOR RECONSTRUCTION AND DEVELOPMENT | 97,577,790 | 9.68% |
| BLOM INVEST BANK S A L | 92,829,048 | 9.21% |
| Omar Mohamed Abdel Gawad | 60,480,063 | 6.00% |
| Total | 391,868,028 | 38.88% |

Board of Directors

The Board consists of 10 members, two independent, six non-executives, including the chairman, and the rest executive members, including the Vice Chairman and the Managing Director. The board has two female representatives. The board's composition exhibits a balance of competency and expertise amongst its members that guarantees the highest level of transparency, accountability, and diversity that would guide the company toward success. The criteria for selecting board members are essentially based on experience and knowledge, covering financial and non-financial elements, and is the paramount duty of the board. The board orchestrates the affairs of the company, sets the business strategy and overall direction, oversees operational, financial, and ethical performance, sets the policy for the company's ethics and integrity, manages the implementation of compensation policies, and

reacts promptly and swiftly to the concerns of the shareholders and stakeholders at large.

Board Structure

| Name | | Shares Owned | | Representation | Executive / Non-Executive |
|------|-------------------------------------|---------------------|-----------------------------|---|---------------------------|
| | | Self-Representation | Legal Entity Representation | | |
| 1 | Rafaat Mokbel Hussein | - | 140,981,127 | Representing Faisal Islamic Bank of Egypt | Non-Executive |
| 2 | Omar Mohamed Abdel Gawad Mahmoud | 60,480,063 | - | Himself | Executive |
| 3 | Mahmoud Mohamed Abdel Gawad Mahmoud | 49,515,566 | - | Himself | Executive |
| 4 | Ahmed Mohamed Abdel Gawad Mahmoud | 46,465,615 | - | Himself | Non-Executive |
| 5 | Mohamad Mohsen Mohamed Mahgoub | 27,563,877 | - | Himself | Executive |
| 6 | Mohamed Mohamed Mohsen Mahgoub | 24,852,865 | - | Himself | Executive |
| 7 | Mohamed Abbas Mohamed Zaki | 18,677,879 | - | Himself | Executive |
| 8 | Abdel Aziz Aly | 1,521,499 | - | Himself | Non-Executive |
| 9 | Hoda Amin Wally | - | - | Herself | Independent |

| | | | | | |
|----|--|---|---|---------|-------------|
| 10 | Sahar Ahmed Mohamad Abdel Moniem naser | - | - | Herself | Independent |
|----|--|---|---|---------|-------------|

Board Committees

Audit and Governance Committee

The Committee convenes at least quarterly and comprises five members, out of which, three independent non-executive members.

Roles and Responsibilities

- Reviews the company's internal controls procedures and ensures compliance;
- Examines accounting policies and changes resulting from applying new accounting standards;
- Analyses and reviews internal audit plan, its mechanism and procedures;
- Analyses and reviews drafting of periodic reports presented to the different managerial levels;
- Examines the methods followed in drafting and reviewing the following:
 - Routine and annual financial statements,
 - Releases of public and private offerings, and
 - Projected balance sheets, including cash flow and income statements.
- Examines initial financial information before presenting it to the board of directors and the financial auditor;
- Responsible for the appointment, compensation and oversight of the work of the auditor and matters related to resignation or dismissal in a manner that does not violate the provisions of the law;
- Assigns tasks to auditors other than reviews of financial statements and gives recommendations on fees in a fashion that safeguards their independence;
- Reviews the auditor's report and follows up on comments and remarks, and settles disputes between the management and the auditor;

- Ensures the submission of a report by an independent advisor on the nature of transactions and acquisitions executed with intended parties and the extent of its harm to the interest of the company or its shareholders;
- Ensures the application of the necessary controls to preserve the company's assets;
- Conducts periodic evaluation of administrative procedures to ensure compliance with the rules and regulations; and
- Prepares reports for the Board of Directors.

ISP created auditing processes that ensure internal compliance of all departments and operations with a mandate to maintain financial accountability and business transparency.

- Developing research and promoting innovative solutions to increase productivity, protect the environment, generate income, and optimise consumption.
- Identifying strategic environmental, social, and governance goals.
- Evaluating the company's long-term ESG performance and contributing to the achievement of its goals.
- Ensuring strategic planning.

Remuneration Committee

The Committee convenes annually and comprises of 3 members (two non-executive members and one independent member. The Committee recommends the remunerations and fees of the directors, executives, and non-executive directors.

Investment Committee

The Investment Committee convenes at least quarterly and comprises four members. The Committee works in conjunction with the Board of Directors.

Roles and responsibilities of the Investment Committee:

- Assists the Board of Directors in executing its obligations related to financial and investment policies and regulations;

- Reviews and evaluates investment opportunities and their alignment with the company's investment strategy;
- Monitors and assesses existing and future holdings and submits its recommendations to the board of directors;
- Supervises the advisory work related to the mandate of the committee, in addition to the tasks assigned by the board of directors;
- Submits audit evaluation reviews of company policies, investments, and funding criteria;
- Conducts studies on core business-related investments;
- Monitors and reviews new investment agreements and offers recommendations for potential investment opportunities;
- Oversees and evaluates the investment portfolio on behalf of the Board of Directors and presents the findings; and
- Monitors investment operations within its work scope.

Sustainability Committee

The Sustainability Committee convenes annually and comprises five members. Sustainability matters are discussed at the board level, and substantial measures and decisions have been taken to minimise the company's environmental footprint. Many initiatives were enacted to make necessary changes in the interest of the business. ISP is committed to reporting on its ESG initiatives and their impact on the community, environment and business performance, outlining its financial and non-financial results. The road to business sustainability entails learning, commitment, engagement, research and innovation. It is essential to keep track of the company's progress toward sustainability, stay focused on its objectives, create sound impact, and assess the effectiveness of our initiatives.

As we aspire to become a responsible business and show our commitment to the environment and the community, we opted to create a sustainability committee to manage our impact. We believe it's an essential step toward steady and sustained growth. In addition, sustainable practices will encourage us to conscientiously and wisely utilise our resources and discover previously unimaginable opportunities for innovation and progress.

In publishing our first sustainability report, the committee members were responsible for outlining our first standalone sustainability report and it is also responsible for formally reviewing and approving our sustainability report and ensuring that all material topics are covered.

Members of the committee were selected based on their qualifications, innovative skills, and level of expertise.

General Assembly

All shareholders are invited to attend the General Assembly. Essential and material topics are raised during the annual General Assembly Meeting to ensure honest disclosure and effective decision-making that primarily benefits the company's and stakeholders' interests. The General Assembly rigorously complies with the rules and regulations of the Egyptian Stock Exchange and the Financial Regulatory Authority.

Disclosure and Internal Controls

ISP enforces policies and procedures to cover the company's transparency and disclosure. The Investor Relations Department (IR) is responsible for disclosing accurate and timely information to the shareholders and stakeholders on the stock exchange disclosure portals and through local and international conferences.

Our disclosure policy ensures ISP's commitment to providing information on its environmental, social, and governance activities transparently and comprehensively. In addition, the policy guarantees prompt and accountable information about the company's ESG performance, strategic direction, and business endeavours to enable investors to make informative decisions.

To better serve our investors, we created an investor relation section on our website specifically designed to provide updated information about the company's ESG performance and make it readily accessible for the investors and shareholders.

Disclosure and engagement methods

- Press Releases
- Quarterly Earnings Releases
- Annual reports
- Annual Board of Directors' Report

- Sustainability reporting
- Meetings and investor conferences


Investors Relations

Many of Ibnsina Pharma's recent investments are technology-based, providing a platform for sector transformation. Expanding and diversifying ISP's business portfolio has become a fundamental pillar in ensuring our business's sustainability. We could maximise shareholders' returns with operational expansions, business differentiation, and strong investor presence.

Our investors play a vital role in the success, development, and growth of Ibnsina Pharma. ISP maintains strong and transparent relations with its investors. We are committed to providing investors with accurate financial and non-financial information about the company. Shareholders are a crucial asset that the company accounts for along its journey. In many ways, our interaction with our shareholders and their feedback and recommendations provides shrewd business insights valuable to the decision-making process and potential ventures that may create value and support the company's core mission. Their insights have optimised the company's financial and non-financial decision-making process and aided ISP in achieving its benchmarks. We strive to create an investment vehicle that realises our investors' aspirations and goals. Additionally, we focus on opening new venues for unique investments that will pave the way for ISP to become a leader in the pharmaceutical logistics industry.

Business accountability is an undeniable element of our business as a publicly listed company, and we communicate this to our investors. Our transparency and openness have strengthened our lines of communication with shareholders, garnered investors' trust, and maintained their confidence. Ibnsina Pharma is committed to protecting the interests of the investors by persistently working to advance and expand the business and build an effective governance model that records top-rank performance.

Our shareholders comprise high calibres respected for their notable works and efforts. With the consistent engagement of our investors, we have become the fastest-growing distribution company maintaining a multi-year record of market-beating, top-line performance. Moreover, our continuous growth and increasing customer base allowed us to upscale and broaden our services and ventures. These



ventures help inspire new ideas that generate integrated solutions enhancing business performance and increasing company value.

Investor Relations manages communications with the shareholders and carries out administrative activities and logistical issues in a reliable and compliant manner. Our communications mainly comprise regularly timed meetings with shareholders, conferences, financial releases, and one-on-one meetings. In addition, we are now committed to publishing an annual sustainability report to disclose our financial and non-financial performance, giving our shareholders a comprehensive understanding of our management approach, corporate strategies, and risk profile.

Compliance

From development and innovation to storage and delivery, medicine is a strategic sector, encompassing some of the world's most vital industries and, as such, is highly regulated. The pharmaceutical industry is meticulous in governance and reporting and requires multiple auditing bodies to ensure quality control and compliance. It imposes rigorous regulations that obligate distributing companies to operate with utmost accountability, transparency, and agility.

ISP is a leader in providing medicine to patients promptly and safely. We take compliance seriously. At ISP, we consider the trust of our suppliers and customers as our main asset. We work hard to obtain this trust and maintain our credibility; in doing so, we focus on acting ethically and incorporating ethical considerations into our business strategy. We achieve this by designing systems, setting processes, and implementing controls to ensure adherence to national laws and regulations and compliance with internal codes and procedures.

When we speak of compliance in ISP, we refer to:

1. Regulatory Compliance
2. Internal Compliance
3. Full adherence to suppliers 'contractual agreements
4. Quality Compliance
5. Safety Compliance

Regulatory changes in the pharmaceutical industry are constantly changing. ISP ensures that it stays ahead of any updates and is tuned to new legislation and changes in regulations to remain compliant. We continually review new

government regulations and changes through the official channels, monitoring the websites of regulatory bodies and government agencies, and enrolling in the public relations agencies' newsletters that provide critical regulatory updates.

The compliance manager's primary responsibility is to protect the company and its employees against any repercussions from non-compliance with laws and regulations and encourage employees to abide by its values and code of ethics.

To ensure compliance, we provide employees training on company values, policies, codes, procedures, internal policies, and applicable laws and regulations. ISP management believes that full compliance and ethical behaviour reveal growth opportunities, and in that spirit, it continuously urges employees to operate responsibly and to do what is right.

Our internal controls include, but are not limited to, policies on anti-bribery, anti-conflict of interest, fair competition, standard operating procedures (SOPs), management of third party and social media guidelines, ISO Standards, and suppliers' quality standards. Our policies, guidelines, and procedures are available for all employees electronically on ISP HR System and in hard copy. All new employees receive training on company policies and procedures upon entry; existing employees receive a yearly refresher. Human Resources evaluates the effect of this activity by assessing employees' knowledge of the policies and procedures, and a reward system has been established to create positive reinforcement. Employee performance reports evaluate employee integrity and compliance, but each employee must adhere to company rules and regulations.

ISP created auditing processes that ensure internal compliance of all departments and operations with a mandate to maintain financial accountability and business transparency.

Therefore, the company's organisational structure required a permanent internal audit department that reports functionally to the Audit and Governance Committee, independent of Executive Management. Internal Audit performs its responsibilities independently as per The International Professional Practices Framework (IPPF). The department created a set of rules and regulations to delineate roles and responsibilities and manages conflicts of interest, working in conjunction with the Audit and Governance Committee. In addition, the department reviews the compliance level of different business functions to ensure proper implementation of company policies and procedures and take the necessary corrective actions where required. The department issues quarterly reviews and presents periodic

assessment reports on company policies and procedures. Its members are appointed based on qualifications and technical expertise, specifically in auditing, finance and accounting.

Whistleblowing

All employees are required to report any suspected misconduct or malpractice. Our internal reporting mechanism allows employees to raise concerns outside line management without fear of reprisal. ISP's whistleblowing mechanism respects the whistle-blower's confidentiality and ensures comprehensive protection and support. HR provides notice regarding the procedures of our internal reporting mechanism and communicates it in writing to all employees. As per company codes and applicable national laws, incidents reported are investigated thoroughly, and management takes action, where deemed necessary.

Risk Management

Risk management is the function of our Compliance Manager. ISP defines risk management as an essential tool to ensure business sustainability and, more importantly, to avoid or reduce the potential adverse effects on our stakeholders, people in the supply chain, and the environment.

According to risk assessment and identification processes, our most conspicuous risks are compliance, operational, financial, reputational, quality and environmental risks, which can impact business continuity. We conduct a risk assessment for each of these risks where we identify the risk, understand it, determine its probability of occurrence, and identify its consequences and impact. We do this based on our internal incidents, violations, and external audit reports. We formulate a plan for avoiding such risks or mitigating their impact. In the Compliance Committee meeting, the Compliance Manager assesses and prioritises each potential risk and presents it to Executive Committee for resolution. A mitigation plan is then designed and endorsed by the Executive Committee. We utilise our various resources such as training employees, raising awareness, drafting procedures, building new warehouses and upgrading existing ones to avoid or mitigate adverse impacts.

Our most crucial risk is a quality risk; the priority that is of utmost importance to us is to bring the medicine to patients promptly and appropriately. The nature of

the business involves risks associated mainly with the storage and distribution of medication. It is a complex process with multiple challenges that may require permitting, closure of warehouses, handling techniques, temperature control, storage mechanisms, transportation, expiration of products, and damages to products. ISP created a set of Standard Operating Procedures to avoid such risks and guarantee business continuity.

Management is highly responsive to any risks that may impact the quality of products. Risk management prioritises issues, designs a business continuity plan assessing possible scenarios and provides potential solutions, and takes the necessary measures to allocate resources to address critical issues directly.

Department heads, together with the quality manager and the risk management team, are responsible for the effectiveness of the risk management process. Together, they present the challenges and potential risks to the Executive Committee to discuss with the CEO and approve actions to avoid or mitigate impacts. Department heads are responsible for the effective implementation of the action plan, and the compliance department follows up on results through set qualitative measures that determine the system's effectiveness.

Anti-Corruption

Our anti-corruption policy is binding on all employees; it reiterates our values and work ethics and governs matters such as bribery, conflict of interest, insider trading, third-party involvement, and social media usage. We have a well-established system that assesses the likelihood of unethical behaviour, its impact, and the mitigation process. ISP in no way tolerates violations of its policy. To eliminate corruption, we have implemented a comprehensive risk management process including tools, techniques, records, a risk register, reporting and documentation procedures, identified roles and responsibilities, scaling and categorising risks, and a risk budget. Our anti-corruption policy addresses interactions with government bodies and public officials. It also addresses gifts, entertainment, grants, and donations; it clearly defines what is accepted and what is not while giving real examples and stating how an employee should act when in doubt. ISP provides training to all new employees on its anti-corruption policies and regular training once a year to all employees and the board of directors. We also offer the training to third parties to disseminate to their teams. In all of its contractual agreements, ISP specifies that adherence to ISP regulations is essential to the continuity of the business relationship. We conduct risk assessments with a

specific focus on corruption across our operations; bribery of government employees is the most significant risk. ISP has a strict approval process for payments made to governmental bodies. The Investigations Manager from Human Resources promptly investigates any policy violation, identifies the root cause, addresses it, and takes the appropriate disciplinary actions were deemed necessary.

Anti-Competitiveness

Our Fair Competition Policy governs our marketing practices and reflects our commitment to free and fair competition. ISP conforms to all national laws and regulations stipulated by the Egyptian Competition Authority. Our policy and code of conduct define what may be considered anti-competitive practice, govern the relationship with trade associations, and encourage employees dealing with these associations to familiarise themselves with the association's antitrust compliance guidance. The policy states the principles of dealing with trade associations, competitors,

Suppliers, and purchasers and the principles of conducting transactions. The approach guides what an employee should do in case of doubt, and training sessions are offered to all employees to familiarise themselves with the policy, its provisions, and potential consequences of its breach.

Board Committees Structure

| # | Member Name | Name of the Committee | | | | Member (Non-Executive/Independent) | Position in the Committee | Joining date |
|---|--------------------------------|---------------------------------------|-----------------------------------|----------------------|-----------------|------------------------------------|--|--------------|
| | | Nomination and Remuneration Committee | Sustainable Development committee | Investment Committee | Audit Committee | | | |
| 1 | Mohamad Mohsen mohamed mahgoub | | √ | √ | | Executive | Chairman of the Investment and Sustainable Development committee | 3/4/21 |
| 2 | Mahmoud Mohamed abdel Gawad | | √ | √ | | Executive | Member of Investment and Sustainable Development | 3/4/21 |

| | | | | | | | | |
|----|--|---|---|---|---|------------------------------|---|--------|
| 3 | Omar Mohamad Abdel Gawad Mahmoud | | | √ | | Executive | Member of the Investment Committee | 3/4/21 |
| 4 | Mohamed Abdel Rahman | | | | √ | Audit Committee Expert | Member of the Audit Committee | 3/4/21 |
| 5 | Mohamad mohamed Mohsen mohamed mahgoub | | √ | √ | √ | Non- Executive | Member of the Audit Committee, the Investment Committee and Sustainable Development | 3/4/21 |
| 6 | Mohamed abass mohamed abass zaki | √ | | | | Non- Executive | Member of the Nomination Committee | 3/4/21 |
| 7 | Abd el Aziz Aly Abdel Aziz | √ | | | √ | Non- Executive | Member of the Audit Committee and Chairman of the Nomination Committee | 3/4/21 |
| 8 | Ahmad Mohamad Abdel Gawad Mahmoud | | √ | | | Non- Executive | Member of Sustainable Development committee | 3/4/21 |
| 9 | Sahar Ahmed Mohamed Nasr | | | | √ | independent | Member of Audit Committee | 3/4/21 |
| 10 | Hoda Hassan amin wally | | √ | | √ | independent | Chairman of the Audit Committee and member of Sustainable Development | 3/4/21 |

* The Ordinary General Assembly On 28/3/2024, elected a new board of directors by acclamation for a period of three years from 2024 to 2026, and it was found that the applicants are only the members of the current board of directors, except for one member (Mr. Ahmed Fathy Abdul Rahman Al-Nawawi), and thus the board of directors was re-elected, taking into account that the formation of the new board includes two

independent members and at least two female elements to comply with the rules of listing in the stock exchange and the rules of governance, and the association appointed Dr. Sahar Ahmed Mohamed Abdel Moneim Nasr

Board members Attendance

| Number | Member Name | Board of Directors | Sustainable Development Committee | Investment Committee | Audit Committee | Nomination and Remuneration Committee |
|--------|---------------------------------------|--------------------|-----------------------------------|----------------------|-----------------|---------------------------------------|
| 1 | Mohamed Mohsen Mohamed Mahgoub | 6/6 | - | - | - | - |
| 2 | Mahmoud Mohamed abdel gawad | 6/6 | - | - | - | - |
| 3 | Omar Mohamed Abdel Gawad Mahmoud | 6/6 | - | - | - | - |
| 4 | Sahar Ahmed Mohamed Nasr | 5/6 | - | - | 1/4 | - |
| 5 | Huda Hussein ameen Wally | 6/6 | - | - | 4/4 | - |
| 6 | Raafat mokbel Hussein | 6/6 | - | - | - | - |
| 7 | Mohmad Mohamad Mohsen Mohamed mahgoub | 6/6 | - | - | 4/4 | - |
| 8 | Mohamed abbas zaki | 5/6 | - | - | - | 1/1 |

| | | | | | | |
|----|--|-----|---|---|-----|-----|
| 9 | Abdel Aziz aly Abdel Aziz | 6/6 | - | - | 4/4 | 1/1 |
| 10 | Ahmad Mohamad Abdel Gawad | 6/6 | - | - | - | - |
| 11 | Ahmad Fathy Abdel Rahman el nawawy | 2/6 | - | - | 1/4 | - |
| 12 | Mohamad Mostafa Abdelrahman El Sayed Mohamed | - | - | - | 4/4 | - |

Auditor

- The Ordinary General Assembly has appointed an auditor and estimated his fees based on a proposal submitted by the Board of Directors of the Company, and the Audit Committee ensures the independence and impartiality of the auditors through:
- Ensure that he is one of the auditors registered in the register of the Financial Regulatory Authority, so that he meets all the conditions contained in the requirements of the Authority's decision regarding the system of registering auditors.
- Ensure that the auditor is independent of the company and its board of directors, and does not carry out additional work for the company that falls within the audit work that may affect impartiality or independence
- The auditor discusses his views with the Audit Committee before submitting the results of the work to the Board of Directors for decision.
- The auditor shall attend the meetings of the general assemblies and read the report prepared by him to the shareholders, explaining any obstacles or interferences encountered by the Board of Directors during the performance of his work.

Insider Trading

| Number | Member Name | Share balance at the Beginning of the year | Shares sold during the year (sold) | Shares purchased during the year (added) | Number of shares owned at the end of the year |
|--------|---|--|------------------------------------|--|---|
| 1 | Omar Mohamad Abdel Gawad Mahmoud Ahmed Abdel Gawad | 56,032,063 | - | 4,448,000 | 60,480,063 |
| 2 | Mahmoud Mohamad Abdel Gawad Mahmoud Ahmed Abdel Gawad | 48,515,566 | - | 1,000,000 | 49,515,566 |
| 3 | *Mohamad Mohsen Mohamad mahgoub | 25,154,798 | | | 27,563,877 |
| 4 | *Mohamed Mohamed Mohsen Mohamad mahgoub | 21,239,247 | | | 24,852,865 |
| 5 | *Heba Mohamed Mohsen Mohamed mahgoub | 13,125,668 | | | 14,932,477 |
| 6 | *Huda Mohamad Mohsen Mohamed mahgoub | 12,673,139 | | | 14,479,948 |
| 7 | *Zeinab Mohamed abass zaki | 9,636,315 | - | - | - |
| 8 | Mohamed Abass Mohamed abass zaki | 18,677,879 | 575,000 | | 18,102,879 |
| 9 | Dalia abbas Mohamed abass zaki | 5,374,707 | 4,730,666 | - | 644,041 |

| | | | | | |
|----|---|-----------|-----------|---------|-----------|
| 10 | Salwa abbas Mohamed abas zaki | 5,374,706 | 3,030,666 | - | 2,344,040 |
| 11 | Rania abbas Mohamed abas zaki | 5,141,239 | 4,497,199 | - | 644,041 |
| 12 | Iman abbas Mohamed abass zaki | 4,900,000 | 4,900,000 | - | - |
| 13 | Omnia abbas Mohamed abbas zaki | 3,374,706 | 3,374,706 | - | - |
| 14 | Bothina abbas Mohamed abbas zaki | 2,207,373 | 1,563,332 | - | 644,041 |
| 15 | Mohamad Mahmoud Shawky Hussein said | 71,053 | 91,053 | 20,000 | - |
| 16 | Moe'men Mohamad Mahmoud Gomaa | 341,656 | 101,656 | 100,000 | 340,000 |
| 17 | Mahmoud Mohamed El Sayed aly el shafei | 20,500 | - | 5 | 20,505 |

*Please note that Zainab Muhammad Abbas Zaki's 9,636,315 shares were distributed according to inheritance notices to the following:

| | |
|---|-----------|
| *Mohamed Mohsen Mohamed Mahgoub | 2,409,079 |
| *Mohamed Mohamed Mohsen Mohamed mahgoub | 3,613,618 |
| *Heba Mohamed Mohsen Mohamed mahgoub | 1,806,809 |
| *Huda Mohamed Mohsen Mohamed mahgoub | 1,806,809 |

Corporate Social Responsibility

We want to grow with our communities. Ibnsina is weaving together its experience and expertise to foster large-scale change to create sustainable communities. Healthcare, education, gender equality, and access to clean water are at the center of our commitment to local community development. Long-term value creation emerges from our longstanding commitment. We believe that the communities in which we operate are essential stakeholders in our business. When setting,

assessing, and tackling our sustainability objectives, we thoroughly consider their concerns, engage with them and work toward their development. Ibnsina Pharma established its local community development approach with a complete understanding of its impact. We conducted research, community screening, and data analysis to create a meaningful plan that effectively responds to sustainability gaps in neighboring communities. Utilizing our core competencies, know-how, and experience increased the depth and effectiveness of the programs we instituted in communities. We believe our presence will be an asset to the communities where we operate.

Establishing good relations with communities surrounding our operations has consistently yielded positive outcomes. We believe success is incomplete if it does not create a positive ripple effect in the lives of vulnerable communities and future generations. This belief drove ISP to fulfil its social role in the most effective manner that can be measured, evaluated, and upscaled.

With a profound belief in the value of collaboration, Ibnsina Pharma is always eager to partner with reliable institutions and organizations to improve and implement sustainable and robust developmental programs. We partner with government entities, NGOs, and private companies to present tangible solutions that will create meaningful differences in Egyptians' lives. To ensure accountability, we obey national laws and international standards in our community activities and partnerships. We endeavor to improve the technical management of our projects

to ensure our work meets our rigorous standards of corporate responsibility. However, we do not engage in religious or political activities, and we don't collaborate or engage with unregistered entities. Ibnsina Pharma invested 5.4 million EGP in 2024 in works related to community engagement.



Abdel Aziz Ali Abdel Aziz



Chairman